AZRX Azurrx Biopharma Inc

AzurRx BioPharma Inc through its subsidiary is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its products under development includes MS1819 and AZ1101.

$0.93
As of 04/09/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/11/2016
Outstanding shares:  74,439,377
Average volume:  6,553,265
Market cap:   $69,228,621
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    05502L105
ISIN:        US05502L1052
Sedol:      BDB2RM6

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   -26.22
PS ratio:   0.00
Return on equity:   1,237.23%
Net income %:   0.00%